AGENUS INC annual report, FY2015

Agenus Inc. — 2015 Form 10-K Summary

Business context and reporting period. Agenus is a clinical-stage immuno-oncology company developing checkpoint-modulating antibodies, cancer vaccines and vaccine adjuvants. This Form 10-K covers the fiscal year ended December 31, 2015; quarterly figures below identify the fourth quarter where relevant. The company had no approved product generating material commercial revenue and reported an accumulated deficit of $779.2 million.

Financial performance and position

Metric	FY 2015	FY 2014
Revenue	$24.8 million	$7.0 million
Research and development expense	$70.4 million	$22.3 million
General and administrative expense	$28.4 million	$21.2 million
Operating loss	$80.7 million	$43.3 million
Net loss	$87.9 million	$42.5 million
Net loss per common share, basic and diluted	$1.13	$0.71
Net cash used in operating activities	$47.2 million	$38.2 million

2015 revenue included approximately $14.4 million of Incyte development-cost reimbursements; revenue also reflected collaboration-related deferred-revenue amortization. Approximately 95% of revenue came from one collaboration partner. No meaningful gross margin is provided in the filing.
Fourth-quarter 2015 revenue was $7.6 million and net loss was $15.6 million, compared with fourth-quarter 2014 revenue of $1.6 million and net loss of $26.0 million.
At December 31, 2015, cash, cash equivalents and short-term investments totaled $171.7 million, versus $40.2 million a year earlier. Current assets were $184.1 million and current liabilities $28.9 million.
Debt principal outstanding was approximately $114.1 million, compared with $6.3 million at year-end 2014. This included $100 million of limited-recourse royalty-backed notes and $14 million of subordinated notes; balance-sheet long-term debt carrying value was $114.3 million.
Stockholders’ equity was $70.7 million, up from $23.0 million. Common shares outstanding rose to 86.4 million from 62.7 million, reflecting equity issuance and acquisition-related shares.

Material changes versus prior year

Revenue increased by $17.8 million, principally reflecting the Incyte collaboration and associated deferred-revenue amortization and cost reimbursements.
R&D expense more than tripled, driven by antibody program spending, acquired in-process R&D, added personnel and licensing costs. G&A expense increased 34%.
Net loss more than doubled. Besides higher operating expenses, interest expense increased to $6.6 million from $1.3 million, mainly due to new 2015 debt. A $5.4 million income-tax benefit related to deferred tax liabilities recorded in acquisitions partially reduced the loss.
Cash increased following financing proceeds, including a $75 million net public offering, $60 million from Incyte collaboration and stock-purchase agreements, and approximately $78 million net from the royalty-backed notes.
Agenus acquired the SECANT antibody discovery platform, PhosImmune’s phosphopeptide technology and XOMA’s antibody pilot manufacturing facility, expanding its platforms and operating footprint.

Outlook, commentary and key risks

Management estimated year-end resources would fund operations through the first half of 2017, based on current plans, and expected to seek additional capital before funds were depleted. It anticipated continued losses and could not reliably estimate when material operating cash inflows might begin.
Management planned to start CTLA-4 and GITR antibody trials in the first half of 2016 and targeted clinical starts for one or more OX40/PD-1 candidates and AutoSynVax in the second half of 2016. A randomized, controlled Prophage trial for newly diagnosed glioblastoma was also targeted for the second half of 2016. These are forward-looking plans, not assured outcomes.
The GSK royalty financing carries 13.5% annual interest, compounded quarterly. Royalties from GSK’s shingles and malaria vaccines are directed to principal and interest; insufficient royalties can result in interest capitalization. The notes include potential 2018 put rights and a later make-whole payment, with Agenus guaranteeing specified obligations. Repayment depends on vaccine approvals and sales, and the company identified potential liquidity impact if guarantee obligations arise.
Clinical and regulatory outcomes remain uncertain. The NCI-sponsored recurrent-glioma Prophage trial was recruiting slowly; most antibody candidates were preclinical or early stage. Prophage’s prior Phase 2 results were compared with historical controls, and none of the company’s Prophage trials had resulted in marketing approval in the filing period.
Other principal risks include dependence on partners—particularly Incyte and GSK—future financing needs, possible dilution, manufacturing and integration challenges, competition, and intellectual-property risks. Janssen had notified Agenus that it was terminating its QS-21 license.
The company reported no material legal proceedings. Management and the independent auditor concluded internal control over financial reporting was effective as of December 31, 2015; the auditor issued unqualified opinions on the financial statements and internal controls.

Most important facts for investors to verify

Whether operating cash burn, clinical spending and new collaboration costs remain consistent with the stated first-half-2017 runway, and what financing may be required.
The terms and guarantees of the royalty-backed notes, including accrued interest, royalty-account mechanics, put rights, make-whole provisions and dependence on GSK vaccine launches and sales.
Actual progress and data from the planned antibody, AutoSynVax and Prophage trials, including enrollment and whether results support the historical-control comparisons.
How much dilution may result from future equity financing, outstanding options and warrants, and acquisition-related milestone payments.
Whether Incyte and other partners continue funding and advancing programs, and whether Agenus can manage the expanded R&D and manufacturing operations within available resources.